Stockscreener 앱 받기
2.05
0.97%
-0.02
전일 마감가:
$2.07
열려 있는:
$2.0601
하루 거래량:
10,465
Relative Volume:
0.66
시가총액:
$5.01M
수익:
$3,000
순이익/손실:
$-4.11M
주가수익비율:
-0.9452
EPS:
-2.1688
순현금흐름:
$-3.23M
1주 성능:
-1.44%
1개월 성능:
+4.06%
6개월 성능:
-34.92%
1년 성능:
-58.45%
1일 변동 폭
$2.00
$2.0933
1주일 범위
$1.98
$2.22
52주 변동 폭
$1.67
$6.20
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
명칭
Alaunos Therapeutics Inc
전화
(346) 355-4099
주소
501 E LAS OLAS BLVD, FORT LAUDERDALE
Compare TCRT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
2.05 | 5.01M | 3,000 | -4.11M | -3.23M | -2.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
Alaunos Therapeutics Inc 주식(TCRT)의 최신 뉴스
MSN Money - MSN
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Stock grant to Alaunos (TCRT) CEO issued in lieu of salary - Stock Titan
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver - The National Law Review
Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study - markets.businessinsider.com
Alaunos Reports New Preclinical Liver Data for ALN1003 - TipRanks
Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market SessionUniverse Pharmaceuticals (NASDAQ:UPC), Deco - Benzinga
Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT) - TradingView
Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alaunos Therapeutics Inc (TCRT) Institutional Confidence - TradingKey
Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary - Stock Titan
Alaunos Therapeutics Inc (TCRT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TCRT Q4 2023 Earnings: EPS Miss Amid Ongoing Clinical DevelopmentEarnings Surprise Report - newsline.com
Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
Number of shareholders of Alaunos Therapeutics, Inc. – NASDAQ:TCRT - TradingView
TCRT Q4 2023 Earnings: EPS Misses Estimates, No Revenue Reported, Stock DeclinesEarnings Stability Report - newsline.com
Alaunos Therapeutics (TCRT) Declines 6.56% as Stock Tests Key Support Near $2.17Swing Trade Setups - newsline.com
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss on Lack of RevenueEstimate Dispersion - dars.gov.et
Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk - Bez Kabli
Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology
Alaunos Therapeutics (TCRT) Declines 4.18% as Biotech Sector Pressure Tests Key Support LevelsQuality ETF - newsline.com
Alaunos Therapeutics Q4 2023 Earnings: EPS Miss Widens as Pre-Revenue Biotech Faces Continued HeadwindsDebt Analysis Report - newsline.com
Alaunos Therapeutics (TCRT) Dips 6.86% as Stock Approaches Critical Support LevelChaikin Flow - The Legal Advocate
TCRT Q4 2023 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Season Outlook - newsline.com
Alaunos Therapeutics (TCRT) CEO takes 3,700 shares instead of salary - Stock Titan
Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers - MSN
Alaunos Therapeutics (TCRT) Drops 2.69% as Support Level Holds SteadyDip Buy Trade - The Legal Advocate
Alaunos Reports Positive Preclinical Metabolic Data for ALN1003 - TipRanks
Alaunos reports preclinical data for obesity drug candidate ALN1003 - Investing.com UK
Alaunos reports preclinical data for obesity drug candidate ALN1003 By Investing.com - Investing.com South Africa
TCRTAlaunos Therapeutics Inc Stock Price and Quote - Finviz
Alaunos Therapeutics Reports Positive Preclinical Results for ALN1003 in Addressing Metabolic Disease Markers - Quiver Quantitative
ALN1003 obesity data and cash runway update from Alaunos (NASDAQ: TCRT) - Stock Titan
TCRT Q4 2023 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No RevenueGuidance Update - Newser
Alaunos Therapeutics (TCRT) Q4 2023 Earnings Fall Short: EPS $-4.90 Misses MarkBuyback Announcement Report - Newser
Alaunos Therapeutics Inc (TCRT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):